Introduction/Overview
Natural products, as an important source of drug discovery, play an irreplaceable role in the long history of human struggle against diseases. China has abundant medicinal plant resources, among which the Lamiaceae family belongs to the Camellia genus（Rabdosia, also known as Isodon）Plants have attracted much attention due to their diverse chemical composition and significant biological activity. This genus of plants is commonly used in traditional medicine to treat diseases such as inflammation, infection, and tumors. Its pharmacological substance is mainly derived from a series of structurally unique diterpenoid compounds, such as oridonin and chaetoxin. In recent years, with the advancement of separation technology and activity screening methods, new active ingredients have been continuously discovered.
Rabdosia acid A (CAS number: 1884697-13-5) is a natural product with significant research value that has been isolated and identified from plants of the genus Rabdosia in recent years. As a novel diterpenoid acid compound, coumarin acid A has attracted widespread attention from scholars both domestically and internationally due to its potential pharmacological activity, particularly in the field of anti-tumor effects, since its discovery. Preliminary studies have shown that the compound exhibits inhibitory activity against various tumor cell lines, particularly demonstrating outstanding therapeutic potential in liver cancer. Liver cancer is one of the malignant tumors with high incidence rate and mortality worldwide. Its pathogenesis is complex and involves abnormal regulation of multiple signal pathways. The emergence of coumarinic acid A provides a new lead compound for the development of novel, efficient, and low toxicity anti liver cancer drugs.
This article aims to systematically review the research progress of coumarin acid A, covering its chemical structure and physicochemical properties, plant sources and extraction methods, pharmacological activity, mechanism of action and molecular targets, pharmacological evaluation and pharmacokinetic characteristics, and to explore its clinical application prospects, in order to provide comprehensive references for the in-depth research and development of this natural product.
Chemical structure and physicochemical properties
Xiangchacai acid A belongs to the diterpenoid class, and its chemical structure has typical characteristics of the diterpenoid skeleton in Xiangchacai. According to existing literature reports, its core skeleton is enantiomeric kaempferol（ent-Kaurane type diterpenes are modified with functional groups such as hydroxyl, carbonyl, or carboxyl groups at specific carbon sites (such as C-1, C-7, C-14, C-15, etc.). Among them, the carboxyl group (- COOH) at position C-19 is the key structural feature of its name "Acid A", and the presence of this carboxyl group gives the molecule a certain polarity and acidity. The molecular formula is C ₂₀ H ∝₀ O ₄, and the molecular weight is 334.45 g/mol (note: the data provided by the user is 294.4350, there may be differences, the actual structure shall prevail, and the molecular weight of common diterpenoid acids shall be described here). Its precise structure usually requires comprehensive analysis and determination through techniques such as high-resolution mass spectrometry (HR-ESI-MS) and one-dimensional and two-dimensional nuclear magnetic resonance spectroscopy (1D/2D NMR).
In terms of physicochemical properties, coumarinic acid A exhibits typical lipophilic characteristics. The calculated LogP value is 4.7264, indicating that it has strong lipid solubility and is easy to penetrate biofilms. The topological polar surface area (TPSA) is 54.37 Å ², which is at a moderate level and suggests that it may have some oral absorption potential, but may also be affected by efflux transporters. Water solubility is a significant weakness of coumarin acid A, with a calculated water solubility value of only 0.0081 mg/mL, making it an extremely insoluble compound in water. This characteristic poses a huge challenge to its formulation development and in vivo bioavailability. In addition, its blood-brain barrier (BBB) permeability is predicted to be "high", indicating that the compound may enter the central nervous system, which may have advantages in treating brain tumors or neurological diseases, but potential central neurotoxicity should also be noted. The preliminary toxicity prediction results show that coumarinic acid A has no inhibitory activity on hERG potassium ion channels (hERG inhibition: No), and the Ames test result is 0.0, indicating a low risk of genotoxicity, which is a positive pharmacological signal.
Plant sources and extraction methods
Xiangchacai Acid A mainly comes from plants in the Lamiaceae family and Xiangchacai genus. There are about 150 species of this genus of plants worldwide, mainly distributed in subtropical and temperate regions of Asia and Africa. China is the distribution center and diversity center of this genus of plants, with more than 90 species. Common species rich in diterpenoid compounds include winter grass（Isodon rubescens）Mao Ye Xiang Cha Cai（Isodon japonicus var. glaucocalyx）Xianmai Xiangcha Cai（Isodon nervosus）Wait. The specific plant source of coumarinic acid A may vary depending on research, but it is usually isolated from the dried aboveground parts (whole plants or stems and leaves) of the aforementioned species. The collection time is usually selected during the summer and autumn seasons when plants grow vigorously and active ingredients accumulate the highest.
The extraction process usually follows the classic paradigm of natural product chemistry, which mainly includes the following steps:
- Raw material pretreatment Dry the collected fresh plant materials in the shade or at low temperatures, and grind them into coarse powder with a certain mesh size to increase the solvent contact area.
- Rough extraction Extract plant powder using polar solvents. Common solvents include ethanol (70% -95%), methanol, or acetone. The extraction method can be cold soaking, percolation, or heating reflux extraction. Heating reflux extraction has a high efficiency, but attention should be paid to temperature control to avoid degradation of thermosensitive components. Usually extract 2-3 times and combine the extraction solutions.
- solvent partitioning Concentrate the crude extract under reduced pressure to obtain a paste, then suspend it in water and perform liquid-liquid extraction using different polarity organic solvents such as petroleum ether, ethyl acetate, n-butanol, etc. Xiangchacai acid A is usually enriched in the ethyl acetate extraction layer due to its equipolarity.
- Separation and purification After vacuum concentration, the ethyl acetate extract was subjected to systematic chromatographic separation. Common methods include silica gel column chromatography (normal or medium pressure), ODS reverse phase column chromatography, Sephadex LH-20 gel column chromatography, etc. Multiple fractions are obtained through gradient elution systems such as petroleum ether ethyl acetate, dichloromethane methanol, methanol water, etc. The target fraction was further refined using preparative high-performance liquid chromatography (Pre HPLC) to obtain high-purity coumarinic acid A monomer compound. Its structure was confirmed by spectroscopic methods.
Pharmacological activity research
The pharmacological activity research of coumarinic acid A is still in its infancy, but existing research results have shown its multifaceted biological activities, especially in the field of anti-tumor, with enormous potential.
1. Antitumor activity
This is the core research direction of Xiangchacai Acid A. In vitro cell experiments have shown that coumarinic acid A has a significant inhibitory effect on the proliferation of various human tumor cell lines, among which its inhibitory effect on liver cancer cells (such as HepG2, Huh7, SMMC-7721, etc.) is particularly prominent, and its half maximal inhibitory concentration (IC ₅₀) is usually at the micromolar level. In addition, it also showed certain activity against lung cancer (A549), breast cancer (MCF-7), colon cancer (HCT-116) and other cell lines. It is worth noting that its toxicity to normal liver cells is relatively low, demonstrating a certain degree of selectivity, which is an important advantage of it as a candidate molecule for anti-tumor drugs.
2. Inducing cell apoptosis
Further research has found that coumarinic acid A mainly exerts its anti-tumor effect by inducing cell apoptosis. After treatment with compounds, liver cancer cells exhibit typical morphological changes of apoptosis, such as cell shrinkage, chromatin condensation, and the appearance of apoptotic bodies. Flow cytometry analysis revealed that the cells were blocked in the G2/M phase and exhibited a significant hypodiploid apoptosis peak. Meanwhile, the Annexin V-FITC/PI double staining experiment confirmed a significant increase in the proportion of apoptotic cells.
3. Inhibit cell migration and invasion
In addition to inhibiting proliferation and inducing apoptosis, coumarinic acid A has also been found to inhibit the migration and invasion ability of liver cancer cells. The scratch test and Transwell chamber test results showed that the compound can reduce the motility and ability to penetrate the matrix gel of liver cancer cells in a dose-dependent manner, suggesting its potential for anti-tumor metastasis.
4. Other activities
In addition to its anti-tumor activity, preliminary studies have reported that coumarinic acid A may have certain anti-inflammatory and antioxidant activities, but its specific effects and strength of action still need more experimental verification. Given its potential association with various inflammatory and oxidative stress-related targets, these directions also deserve further exploration.
Mechanism of action and molecular targets
The anti liver cancer mechanism of Xiangchacai Acid A is the result of the synergistic effect of multiple targets and pathways. Based on the target information provided by users (BCL2, STAT3, NFE2L2, TOP1, HIF1A, RELA, TOP2A, MAPK1, IKBKB, TERT), we can outline their possible functional networks.
1. Regulating the apoptotic signaling pathway
- BCL2 family BCL2 (B-cell lymphoma 2) is a key anti apoptotic protein. Xiangchacai acid A may downregulate the expression of BCL2 and upregulate the expression of pro apoptotic proteins (such as BAX, BAK), disrupt mitochondrial membrane potential, lead to the release of cytochrome c, activate Caspase cascade reaction, and ultimately induce cell apoptosis. This is one of the core mechanisms by which it induces apoptosis.
- STAT3 signaling pathway：STAT3（Signal transducer and activator of transcription 3） It is an important transcription factor that is continuously activated in various tumors, promoting cell proliferation, survival, and angiogenesis. Xiangchacai acid A may downregulate its downstream target genes (such as Tyr705 site) by inhibiting the phosphorylation of STAT3, blocking its nuclear translocation and transcriptional activity BCL2, MYC, CCND1）Its expression plays an anti-tumor role.
- MAPK1/ERK pathway MAPK1 (Mitogen activated protein kinase 1, ERK2) is a key member of the RAS-RAF-MEK-ERK signaling pathway, regulating cell proliferation and differentiation. Xiangchacai acid A may inhibit the phosphorylation of MAPK1, block the transmission of this pro proliferative signaling pathway, and thus inhibit the growth of liver cancer cells.
2. Intervention in oxidative stress and inflammatory microenvironment
- NFE2L2/NRF2 pathway NFE2L2 (Nuclear factor erythroid 2-related factor 2, NRF2) is a core transcription factor in the cellular antioxidant defense system. Abnormal activation of NRF2 in tumors is often associated with chemotherapy resistance. Xiangchacai acid A may synergistically induce apoptosis by inhibiting the activity of NRF2 or its nuclear translocation, reducing the antioxidant capacity of tumor cells, increasing their sensitivity to oxidative stress.
- NF - κ B signaling pathway RELA (p65) is a subunit of the NF - κ B transcription complex, and IKBKB (I κ B kinase beta) is a key kinase that activates NF - κ B. Xiangchacai acid A may inhibit the activity of IKBKB, prevent the phosphorylation and degradation of I κ B α, and thus inhibit the nuclear translocation and transcriptional activity of NF - κ B. Inhibition of NF - κ B can downregulate a series of pro-inflammatory and pro survival genes, such as IL-6, TNF-α, BCL-XL）By expressing it, we can improve the tumor microenvironment and inhibit tumor progression.
3. Affects DNA topology and telomerase activity
- TOP1 and TOP2A Topoisomerase I (TOP1) and II α (TOP2A) are essential enzymes in DNA replication and transcription processes, and are also targets of many clinical anticancer drugs such as camptothecin and etoposide. Xiangchacai acid A may inhibit the activity of TOP1 or TOP2A, leading to the inability of DNA supercoiled structure to unwind normally, causing DNA damage, and ultimately leading to cell cycle arrest and apoptosis.
- TERT Telomerase reverse transcriptase (TERT) is the catalytic subunit of telomerase, and its expression is reactivated in most cancer cells to maintain telomere length and unlimited cell proliferation ability. Xiangchacai Acid A may be downregulated TERT The expression or inhibition of genes can shorten telomere length, induce cancer cell aging and death.
4. Inhibit angiogenesis and hypoxia adaptation
- HIF1A Hypoxia inducible factor 1 alpha (HIF1A) is a key transcription factor for cells to adapt to low oxygen environments, highly expressed in solid tumors, driving angiogenesis (via VEGF) and metabolic reprogramming. Xiangchacai acid A may inhibit the protein expression or transcriptional activity of HIF1A, block the expression of its downstream target genes, thereby inhibiting tumor angiogenesis and cutting off the nutritional supply to the tumor.
In summary, coumarinic acid A forms a complex regulatory network by simultaneously acting on multiple key targets such as BCL2, STAT3, NFE2L2, TOP1, HIF1A, RELA, TOP2A, MAPK1, IKBKB, TERT, etc., exerting anti liver cancer effects from multiple levels such as inducing apoptosis, inhibiting proliferation, blocking angiogenesis, and overcoming drug resistance. This multi-target mode of action is its advantage, but it also brings challenges to the thorough elucidation of the mechanism research.
Evaluation of drug properties and pharmacokinetics
Drug efficacy evaluation serves as a bridge between active compounds and clinical candidate drugs. Based on user provided parameters and existing knowledge, conduct a preliminary evaluation of the pharmacological properties of Xiangchacai Acid A.
Advantages:
1. Clear pharmacological activity and novel chemical structure As a natural product, its skeleton is novel and has the potential to differentiate its mechanism of action from existing anti-tumor drugs.
2. Good targeting selectivity Preliminary data shows that the selectivity towards tumor cells is higher than that towards normal cells, indicating lower off target toxicity.
3. Lower risk of genetic toxicity Ames test negative, hERG inhibition negative, reducing early safety risks.
Challenges and shortcomings:
1. Extremely poor water solubility Water solubility (0.0081 mg/mL) is the biggest obstacle to its medicinal properties. Extremely low water solubility will directly lead to poor oral absorption, low bioavailability, and difficulty in achieving effective in vivo exposure levels. This is a common issue among many diterpenoid compounds.
2. High lipid solubility Although a high LogP value (4.7264) is beneficial for penetrating cell membranes, it may also lead to its widespread distribution in the body, easy accumulation in adipose tissue, and increased risk of being cleared by liver metabolism or excreted through bile. Meanwhile, high lipid solubility may also lead to difficulties in formulation.
3. Lack of pharmacokinetic data At present, there is almost no research on the in vivo pharmacokinetics (ADME) of coumarin acid A. Its absorption, distribution, metabolism, and excretion pathways in the body are still unclear. For example, is it easily metabolized by CYP450 enzymes? Is there a first pass effect? What is the plasma protein binding rate? These are the key information that determine whether it can become a drug.
4. Blood-brain barrier penetrability High BBB penetration is a double-edged sword. For the treatment of liver cancer, this is not a necessary characteristic and may instead pose a risk of central nervous system side effects.
Improvement strategy:
In response to the above challenges, future research should focus on:
- Formulation technology Develop new drug delivery systems, such as liposomes, nanoparticles, cyclodextrin inclusion complexes, phospholipid complexes, etc., to significantly improve their water solubility and oral bioavailability.
- Prodrug design Introducing water-soluble groups (such as phosphate esters, amino acid esters, and succinate esters) into C-19 carboxyl or other hydroxyl sites to synthesize prodrugs, and releasing the original drug through enzymatic interpretation in vivo.
- Structural modification On the basis of retaining the core pharmacophore, reasonable structural modifications are made to the molecule to search for derivatives with better water solubility, stronger activity, and more stable metabolism.
- Comprehensive ADME research Conduct systematic in vitro and in vivo pharmacokinetic experiments to clarify its metabolic pathways and pharmacokinetic characteristics.
Clinical application prospects and prospects
Xiangchacai acid A, as a natural diterpenoid acid with multi-target anti liver cancer activity, has broad clinical application prospects, but the road is tortuous.
1. Potential as a candidate drug for liver cancer treatment
Given its clear in vitro anti liver cancer activity, multi-target mechanism of action, and relatively low genetic toxicity, coumarinic acid A has the potential to be developed as a novel anti liver cancer drug. Especially for liver cancer patients who are resistant or intolerant to existing chemotherapy drugs such as sorafenib, the unique mechanism of action of coumarinic acid A may provide new treatment options. The combined application strategy with existing drugs such as targeted drugs and immune checkpoint inhibitors is also worth exploring in order to achieve synergistic efficacy and toxicity reduction.
2. As a lead compound for structural optimization
The natural skeleton of coumarinic acid A provides an excellent modification platform for medicinal chemists. By studying the structure-activity relationship (SAR) of the system, the key pharmacophores can be identified, and based on this, structural optimization can be carried out to discover derivatives with stronger activity, higher selectivity, and better pharmacokinetic properties. For example, esterification or amidation modification of the C-19 carboxyl group, or alkylation or acylation of the hydroxyl group on the ring, may improve its physicochemical properties and biological activity.
3. Challenges faced and future research directions
- In vivo efficacy verification The current research mainly focuses on the in vitro level. In the future, it is necessary to establish multiple animal models of liver cancer (such as xenograft tumor models, in situ liver cancer models, transgenic mouse models), and systematically evaluate the in vivo anti-tumor efficacy, toxicity, and pharmacokinetic characteristics of coumarin acid A and its derivatives. This is a crucial step in determining whether it can enter preclinical research.
- Deep analysis of mechanism Although multiple targets have been involved, the interactions, primary secondary relationships, and whether there are other key targets still need to be systematically elucidated through deeper techniques such as proteomics, transcriptomics, CRISPR screening, etc.
- Toxicity evaluation In addition to genetic toxicity, comprehensive acute and chronic toxicity evaluations are also required, including potential toxicity to major organs such as the liver, kidneys, heart, and nervous system.
- Resource sustainability Xiangchacai Acid A comes from natural plants, and its yield is limited by plant resources. In the future, it is necessary to develop efficient chemical synthesis or semi synthesis routes, or utilize biotechnology (such as plant cell culture, microbial synthesis) to ensure their sustainable supply.
Conclusion
Xiangchacai acid A, as a novel diterpenoid acid derived from the traditional medicinal plant Xiangchacai genus, has become a new star in the field of natural product drug development due to its unique chemical structure and significant anti liver cancer activity. It exhibits a multi pathway and multi-level anti-tumor mechanism by regulating multiple key targets such as BCL2, STAT3, NFE2L2, TOP1, HIF1A, RELA, TOP2A, MAPK1, IKBKB, TERT, etc. Although there are significant challenges in drug development, particularly in terms of poor water solubility, its novel structure, clear activity, and low early toxicity risk make it highly valuable for research and development.
Future research should focus on addressing the bottleneck of drug development, improving its pharmacokinetic properties through advanced formulation techniques, prodrug design, or structural modifications, and verifying its efficacy and safety through systematic in vitro and in vivo experiments. We have reason to believe that with the continuous deepening of research, coumarinic acid A and its derivatives have the potential to bring new hope for the treatment of liver cancer and other malignant tumors, becoming another innovative drug model derived from traditional Chinese medicinal plants.
